Market Place
Sourcing Support
Valbiotis Presents the Full Results of the Phase II/III REVERSE-IT Study
11 Sep 2023 //
ACCESSWIRE
Valbiotis Announces the Large Success of Phase II/III Study on TOTUM•63
22 May 2023 //
BUSINESSWIRE
Valbiotis Publishes Its 2022 Annual Results
15 Mar 2023 //
BUSINESSWIRE
Valbiotis Announces Positive Results in Bioavailability and Mode of Action TOTUM
30 Jan 2023 //
BUSINESSWIRE
Valbiotis: a Pivotal Year in the Execution of Its Clinical & Commercial Strategy
10 Jan 2023 //
BUSINESSWIRE
Valbiotis Successfully Completes a Fundraise of 9.7 Million Euros
09 Nov 2022 //
BUSINESSWIRE
Valbiotis Accelerates Its Marketing Strategy
07 Oct 2022 //
BUSINESSWIRE
Valbiotis Publishes Its Financial Report for the First Half of 2022
15 Sep 2022 //
BUSINESSWIRE
Frédéric PELONG, Chief Financial Officer, Joins the Valbiotis Board of Directors
05 Sep 2022 //
BUSINESSWIRE
Valbiotis Announces First Visit of First Patient in TOTUM•63 MOA Clinical Study
28 Apr 2022 //
BUSINESSWIRE
Valbiotis Shows Positive Results on Bioavailability and MOA of TOTUM•070
28 Mar 2022 //
BUSINESSWIRE
Valbiotis is Strengthening Its Commitment to CSR
22 Mar 2022 //
BUSINESSWIRE
Valbiotis Publishes Its 2021 Annual Report
15 Mar 2022 //
BUSINESSWIRE
Valbiotis Presents Its 2022 Financial Communication Calendar
24 Feb 2022 //
BUSINESSWIRE
Valbiotis Nabs Approval to Launch Two Phase II/III Clinical Studies of TOTUM•854
17 Feb 2022 //
BUSINESSWIRE
Valbiotis Announces Positive Preclinical Results for TOTUM•070 in(AHA)
13 Nov 2021 //
BUSINESSWIRE
Valbiotis: Activities & Publishes Its Financial Report for First Half of 2021
30 Sep 2021 //
BUSINESSWIRE
Valbiotis publishes its 2021 letter to shareholders
09 Sep 2021 //
BUSINESSWIRE
Valbiotis Recruitment Completed for Phase II HEART Clinical Study of TOTUM•070
07 Sep 2021 //
BUSINESSWIRE
Valbiotis Completed Recruitment for the Phase II HEART Clinical Study
06 Sep 2021 //
FIRSTWORD PHARMA
Valbiotis Announces INAF 1 to Conduct Clinical Study of TOTUM-63
29 Jun 2021 //
BUSINESSWIRE
Valbiotis Announces the Implementation of the TOTUM•63 Mode of Action
28 Jun 2021 //
BUSINESSWIRE
Valbiotis named Sébastien Bessy as Chief Operating Marketing & Business Officer
08 Jun 2021 //
BUSINESSWIRE
VALBIOTIS Selected to Present TOTUM-854’s Results at the Meeting of ESH and ISH
08 Mar 2021 //
BUSINESSWIRE
VALBIOTIS selected to present TOTUM-854’s results
08 Mar 2021 //
PRESS RELEASE
VALBIOTIS the First Patient’s First Visit in the Ph II HEART on TOTUM-070
22 Feb 2021 //
BUSINESSWIRE
VALBIOTIS to begin trial of TOTUM-070 for LDL-cholesterol treatment
16 Feb 2021 //
CLINICALTRIALSARENA
VALBIOTIS Presents the First Market Data on Untreated LDL For TOTUM-070
27 Oct 2020 //
BIOSPACE
VALBIOTIS Presents the First Market on LDL-hypercholesterolemia For TOTUM-070
27 Oct 2020 //
BUSINESSWIRE
VALBIOTIS Integrates The EnterNext© PEA-PME 150 Index From Euronext Paris
05 Oct 2020 //
BUSINESSWIRE
Valbiotis’ TOTUM-070 to reduce LDL-cholesterol in blood receives patents
15 Sep 2020 //
PHARMABIZ
VALBIOTIS Announces the First Patient First Visit in the International PhII/III
15 Jul 2020 //
BUSINESSLWIRE
Authorization to Launch the International Ph II/III REVERSE-IT Study
07 Jul 2020 //
BUSINESSWIRE
